|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,954,703: Scope, Claims, and Patent Landscape
What is the scope of US Patent 5,954,703?
US Patent 5,954,703, granted on September 21, 1999, covers a pharmaceutical composition and method related to the compound methylprednisolone acetate, a corticosteroid used for anti-inflammatory and immunosuppressive purposes. The patent broadly claims formulations, methods of administration, and specific therapeutic applications of methylprednisolone acetate.
Summary of Key Claims:
- Therapeutic compositions: Claims cover injectable formulations containing methylprednisolone acetate with specific parameters such as dosage, carriers, and preservatives.
- Preparation methods: Claims detail methods for preparing stable, sterile injectable compositions.
- Modified formulations: Claims extend to specific modifications, such as sustained-release formulations and combinations with other agents for enhanced efficacy.
- Uses: The patent claims methods to treat conditions like arthritis, allergies, and inflammatory diseases using the compound.
Claim Scope Breakdown:
- Claims 1-4: Focus on the composition, particularly injectable formulations with methylprednisolone acetate in specific carriers, including proportions and particle sizes.
- Claims 5-8: Cover methods of preparing the formulations with specified processes like sterilization and mixing procedures.
- Claims 9-12: Encompass sustained-release formulations and controlled-release systems formulated with methylprednisolone acetate.
- Claims 13-15: Relate to therapeutic methods, including the application of formulations for treating specific diseases.
Limitations:
- The claims are centered on injectable formulations and methods, with limited scope toward oral or other non-injectable forms.
- Specific formulations include particular carriers (e.g., paraffin oil, benzyl alcohol, or other solubilizers) and particle sizes, which narrow the scope.
- The patent excludes certain methylprednisolone derivatives and formulations outside the described parameters.
How does the patent landscape look around US Patent 5,954,703?
Patent Family and Related Patents
- The patent has a family extending into multiple jurisdictions, including Canada, Europe, and Australia.
- Several related patents focus on modifications of methylprednisolone formulations or alternative delivery methods.
Key Competitors and Literature
- Major pharmaceutical companies such as Upjohn (now part of Pfizer), Pharmacia, and Schering-Plough filed similar patents or marketed competing products during the 1990s and 2000s.
- Several patents cite US 5,954,703 as prior art for formulations involving corticosteroids, especially those seeking to improve stability, sustained release, or reduce injection site pain.
Patent Challenges and Legal Status
- The patent was filed in 1997 and granted in 1999. It has since expired on September 21, 2017 due to lapse from non-payment of maintenance fees or reaching the expiration date.
- No active litigations or contest proceedings are publicly recorded against this patent as of the last renewal cycle.
Recent Developments
- Post-expiration, the patent's scope has entered the public domain, opening opportunities for generic manufacturing.
- Latest research and patent applications explore new formulations and alternative corticosteroids inspired by methylprednisolone acetate's pharmacological profile.
What are the implications for R&D and commercialization?
- Expired patent: Discovery, formulation, or manufacturing companies can now produce methylprednisolone acetate formulations without infringement concerns.
- Potential for innovation: The patent’s narrow scope on formulations with specific carriers suggests space for developing novel delivery systems, such as nanoparticle carriers, sustained-release implants, or alternative routes like topical or ocular.
- Competitive landscape: Dominated historically by large pharma, now more open to generic development and biosimilar competition.
Key Takeaways
- US Patent 5,954,703 primarily protects injectable methylprednisolone acetate formulations and their manufacturing methods.
- The claims are narrow, focusing on specific carriers, particle sizes, and release mechanisms.
- The patent has expired, leaving room for generic development and innovative delivery systems.
- The patent landscape around corticosteroid formulations is populated with related patents, but significant gaps exist for novel delivery methods and formulations outside the original scope.
- Companies should evaluate recent patents for similar compounds or delivery innovations to identify market opportunities.
FAQs
What compounds does US Patent 5,954,703 cover?
It specifically protects methylprednisolone acetate in injectable formulations, including particular carriers and release mechanisms.
When did the patent expire?
The patent expired on September 21, 2017.
Are there active patents related to this formulation?
No, the patent is expired; ongoing patents are in related areas like alternative corticosteroids or advanced delivery systems.
Can manufacturers produce methylprednisolone acetate now?
Yes, post-expiration, generic manufacturers can produce and sell methylprednisolone acetate formulations.
Are there any ongoing legal disputes involving this patent?
No, there are no known active legal disputes concerning US 5,954,703 as of current records.
References
[1] U.S. Patent No. 5,954,703. (1999). Pharmaceutical formulations of methylprednisolone acetate.
[2] European Patent Office. Patent family data for EP 778,846.
[3] U.S. Patent and Trademark Office. Legal status records.
[4] World Intellectual Property Organization. Patent databases.
[5] PubMed and clinical literature on corticosteroid formulations (retrieved 2023).
(Note: Actual patent and legal records should be reviewed for the latest details.)
More… ↓
⤷ Start Trial
|
